Emerging Paradigms in Delivery Systems for Antitubercular Therapy

1st Edition - April 23, 2025
Imprint: Academic Press
Editors: Rajeev Sharma, Neeraj Mishra, Laxmikant Gautam, S.P. Vyas
Language: English
Paperback ISBN:
9 7 8 - 0 - 4 4 3 - 2 4 0 3 5 - 5
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 2 4 0 3 4 - 8

Emerging Paradigms in Delivery Systems for Antitubercular Therapy provides an up-to-date and thorough overview of the state-of-the-art of concepts, design, and recent advances… Read more

Purchase options

BLOOM INTO SPRING SAVINGS

Save up to 25% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Emerging Paradigms in Delivery Systems for Antitubercular Therapy provides an up-to-date and thorough overview of the state-of-the-art of concepts, design, and recent advances in nanomedicines and nanobiotechnology-based strategies for the treatment of tuberculosis. The book enables researchers to prepare a variety of nanotechnology-based strategies, investigate their properties, and discover their uses and applications in antitubercular therapy, focusing on advanced nanomaterials that are utilized for encapsulation of nucleic acid, mRNA, DNA, and tuberculosis vaccination.

This book covers all major topics that have shaped the development of nanomedicine and propelled it to its current place at the forefront of Nanotechnology based treatment innovation. It will be a welcomed resource for researchers and readers with more and more challenging therapy and biologicals with their possible modifications to be used for the effective therapy of tuberculosis.

Title of Book
Cover image
Title page
Table of Contents
Copyright
List of contributors
Chapter 1 Introduction: An overview of novel approaches for the treatment of tuberculosis
Abstract
1.1 Introduction
1.2 Morbific of tuberculosis
1.3 Current therapies available for tuberculosis
1.4 Limitation of current therapies
1.5 Novel drug conveyance arrangements for tuberculosis
1.6 Novel delivery systems
1.7 Clinical trials involved in novel formulations for tuberculosis
1.8 Toxicity studies of novel formulation
1.9 Patents on novel formulation for tuberculosis
1.10 Conclusion
References
Chapter 2 Theragnostic approaches for the management of tuberculosis
Abstract
2.1 Introduction
2.2 Tuberculosis: classification and therapeutic options
2.3 Conventional dosage forms for tuberculosis
2.4 Novel drug delivery systems for tuberculosis management
2.5 Theragnostic approaches for tuberculosis management
2.6 Conclusion and future perspectives
References
Chapter 3 Role of metallic nanoparticles in the treatment of tuberculosis
Abstract
3.1 Introduction
3.2 Pathophysiology of tuberculosis
3.3 Challenges for drug delivery in drug-resistant tuberculosis
3.4 Metal nanoparticles-driven strategies for the treatment of tuberculosis
3.5 Regulatory overview and toxicity of metal nanoparticles
3.6 Conclusion and future prospects
Acknowledgment
References
Chapter 4 Role of biodegradable polymeric nanoparticles for the treatment of tuberculosis
Abstract
4.1 Introduction of nanomaterials
4.2 Advance methods for preparation of nanoparticles
4.3 Biodegradable polymeric nanocarriers for the delivery of antitubercular drugs
4.4 Conclusion
References
Chapter 5 Role of vesicular nanocarriers for the treatment of tuberculosis
Abstract
Abbreviations
5.1 Introduction
5.2 Barriers and strategies to overcome in tubercular disease
5.3 Conventional therapies
5.4 Limitations of conventional therapy
5.5 Need for nanocarriers-based drug delivery system in tuberculosis management
5.6 Various vesicular nanocarriers and targeting approaches in tuberculosis management
5.7 Advanced application of vesicular nanocarriers
5.8 Potential toxicity of vesicular nanocarrier and immune response
5.9 Current clinical status and regulatory translation
5.10 Future prospectives and challenges in commercialization
References
Chapter 6 Role of carbon nanotubes for the treatment of tuberculosis
Abstract
6.1 Introduction
6.2 Macrophage: the cellular tropics of Mycobacterium tuberculosis
6.3 Challenges with current tuberculosis chemotherapy
6.4 Need for engineered nanoconstructs
6.5 Role of carbon nanomaterials in the treatment of tuberculosis
6.6 In vivo toxicity of carbon nanomaterials
6.7 Role of carbon nanotubes for the treatment of tuberculosis
6.8 Conclusions
References
Chapter 7 Role of the gut lung axis and microbiota based approaches in the treatment of tuberculosis
Abstract
7.1 Introduction
7.2 Tuberculosis
7.3 Microbiota and tuberculosis
7.4 The gut–lung axis in tuberculosis
7.5 Microbiota-based therapeutic approaches used for the treatment of tuberculosis
7.6 Conclusion
References
Chapter 8 Mucoadhesive polymeric nanocarriers for the treatment of tuberculosis
Abstract
8.1 Introduction
8.2 Current approaches to tuberculosis treatment and their limitations
8.3 Mucoadhesion in drug delivery: an overview
8.4 Applications of mucoadhesive drug delivery systems
8.5 Mucoadhesion
8.6 Applications of mucoadhesives in the treatment of tuberculosis
8.7 Conclusion
References
Chapter 9 Recent gene therapy approaches for the treatment of tuberculosis
Abstract
9.1 Introduction
9.2 Gene delivery mechanisms: viral and nonviral vectors
9.3 Characteristics of viral vectors used in gene therapy treatment of tuberculosis
9.4 Recent advances in tuberculosis gene therapy
9.5 Challenges and considerations
9.6 Conclusion
References
Chapter 10 Novel targets and drugs for the treatment of tuberculosis
Abstract
10.1 Introduction
10.2 Cell wall biosynthesis
10.3 Peptidoglycans synthesis
10.4 Mycolic acid
10.5 Arabinogalactan biosynthesis
10.6 Amino acid biosynthesis
10.7 Branched-chain amino acid biosynthesis
10.8 Cofactor biosynthesis
10.9 Pantothenic acid biosynthesis
10.10 Coenzyme A biosynthesis
10.11 Riboflavin biosynthesis
10.12 Mycothiol biosynthesis
10.13 Terpenoid biosynthesis
10.14 Glyoxylate shunt pathway
10.15 Targeting regulatory proteins
10.16 Menaquinone biosynthesis
10.17 DNA synthesis
10.18 Methionine aminopeptidase
10.19 Toward enlarging the target space for oxidative phosphorylation
10.20 Role of nanotechnology
10.21 Passive targeting
10.22 Passive targeting of antitubercular
10.23 Active targeting
10.24 Mannose receptor targeting
10.25 Folate receptor targeting
10.26 Hyaluronic acid receptor targeting
10.27 Tuftsin receptor targeting
10.28 Formyl peptide receptor
10.29 Other receptors
10.30 Challenges associated with the development of antitubercular candidates with novel targets
10.31 Current and future perspective
10.32 Conclusion
Acknowledgment
Declaration of interest
References
Chapter 11 Multidrug resistance complexity of Mycobacterium tuberculosis and oxidative stress: the need for innovative drug delivery strategies
Abstract
11.1 Introduction
11.2 Challenges in treatment of tuberculosis
11.3 Classification
11.4 Unique features
11.5 Evolution
11.6 Epidemiology of tuberculosis
11.7 Global and national epidemiology
11.8 The challenges of drug resistance
11.9 Drug resistance and fitness
11.10 Mutation rate
11.11 Treatment of tuberculosis
11.12 Multidrug resistant and extensively drug resistant tuberculosis
11.13 Susceptibility testing
11.14 Alternatives to antibiotics
11.15 Nanoparticles
11.16 Oxidative stress contribution to antituberculosis drug resistance
11.17 Development of new antituberculous drugs
11.18 Innovative drug delivery strategies
11.19 Nanoantimicrobials
11.20 New drugs or new chemical entities
11.21 Herbal drugs
11.22 Recent trials of new tuberculosis drugs and regimens
11.23 Conclusion
References
Chapter 12 Role of biosensors as an alternative approach for the treatment of tuberculosis
Abstract
12.1 Introduction
12.2 Types of biosensor
12.3 Biosensors development for the treatment of tuberculosis
12.4 Challenges in the development of biosensor
12.5 Application of biosensor in tuberculosis
12.6 Conclusion
References
Chapter 13 Recent approaches for the treatment of multidrug resistance tuberculosis
Abstract
13.1 Introduction
13.2 Global extent of multidrug resistance tuberculosis
13.3 Obstacle to the management of multidrug resistance tuberculosis
13.4 Recent treatment approaches for multidrug resistance tuberculosis
13.5 Conclusion
Acknowledgment
References
Chapter 14 Targeted drug delivery to the macrophagic cellular tropics in tuberculosis
Abstract
14.1 Introduction
14.2 Macrophage and its role in tuberculosis pathogenesis
14.3 Drug resistance: a major challenge in tuberculosis treatment
14.4 Targeting macrophages for enhanced drug delivery: a potential solution
14.5 Macrophage-targeted drug delivery
14.6 Challenges associated with macrophage targeting
14.7 Conclusion and future prospectives
Acknowledgment
References
Chapter 15 Tuberculosis vaccines: advancements and on-going clinical trials
Abstract
15.1 Introduction
15.2 Pathogenesis of tuberculosis
15.3 Nucleic acid vaccine
References
Chapter 16 Impact of socioeconomic factors on the treatment of tuberculosis
Abstract
Abbreviations
16.1 Introduction
16.2 Impact of social and economic factors on tuberculosis
16.3 Barriers to accessing the tuberculosis treatment programs
16.4 Potential actions for overcoming barriers to access tuberculosis healthcare services
16.5 Harnessing resources to deliver tuberculosis treatment
16.6 Conclusion and future perspectives
Acknowledgments
References
Chapter 17 Future prospects and clinical aspects for the management of tuberculosis
Abstract
17.1 Introduction
17.2 Present status of clinical research for tuberculosis treatment
17.3 Present diagnostic tests for tuberculosis infection
17.4 New diagnostics in tuberculosis
17.5 Initiatives to shorten the duration and effectiveness of tuberculosis treatment
17.6 Summary and conclusion
References
Index

Rajeev Sharma

Rajeev Sharma is an Assistant Professor at the Amity Institute of Pharmacy, Amity University, Madhya Pradesh, Gwalior, India. He earned his B.Pharm, M.Pharm, and Ph.D. in Pharmaceutical Sciences from Dr. H. S. Gour Central University, Sagar, India. Dr. Sharma has approximately 13 years of experience in both teaching and industry. He has served as a Junior Research Fellow under AICTE, an ICMR-SRF, and a CSIR-RA Fellow during his research career, and has worked as an Assistant Professor in academia and as a Senior Formulation Development Scientist in the R&D industry. Dr. Sharma has edited two international and two national books and has authored over 30 publications and 21 book chapters in international reference books. His work focuses on recent concepts in immunology, nanobiotechnology, novel drug delivery systems, and targeted and controlled drug delivery of bioactives for the treatment of diseases such as cancer and diabetes. He is a life member of the Association of Pharmaceutical Teachers of India (APTI). Dr. Sharma's work has been cited approximately 1,200 times, and he has an h-index of 17. The cumulative impact factor of his published papers is around 120, according to SCOPUS. He is currently working on a research project funded by the Madhya Pradesh Council of Science and Technology (MPCST). Dr. Sharma has received several awards for his research, including the Young Research Scholar award and various awards for best oral and poster presentations at national and international conferences. His current research interest is in nanocarrier-based targeted approaches for the effective delivery of bioactives.

Affiliations and expertise

Assistant Professor, Amity institute of Pharmacy, Amity University, Gwalior, Madhya Pradesh, India

Neeraj Mishra

Dr. Neeraj Mishra is a Professor and Head of the Department of Pharmaceutics at Amity Institute of Pharmacy, India, a position he has held since July 2019. With nearly two decades of teaching and research experience, Dr. Mishra has authored over 100 publications on novel drug delivery systems, focusing on nanocarriers and microparticles for treating breast and colon cancer, as well as neurodegenerative disorders. He has written several books and book chapters, and holds three international and two Indian patents. Dr. Mishra has received numerous accolades, including the "Distinguished Professor Award" (2019, 2021) and the "Outstanding Scientist Award" (2020). He has served as a guest editor for Bentham Sciences and is recognized in Stanford University's World Scientists Rankings for 2022 and 2024.

Affiliations and expertise

Professor and Head of Department, Amity Institute of Pharmacy, Amity University, India

Laxmikant Gautam

Laxmikant Gautam is a PhD Scholar in the Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, Madhya Pradesh, India.

Affiliations and expertise

PhD Scholar, Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, Madhya Pradesh, India

S.P. Vyas

Professor S.P. Vyas works in the Department of Pharmacy, Dr. Harisingh Gour University, Sagar, Madhya Pradesh, India.

Affiliations and expertise

Professor, Department of Pharmacy, Dr. Harisingh Gour University, Sagar, Madhya Pradesh, India

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health

Emerging Paradigms in Delivery Systems for Antitubercular Therapy

Purchase options

BLOOM INTO SPRING SAVINGS

Institutional subscription on ScienceDirect

Rajeev Sharma

Neeraj Mishra

Laxmikant Gautam

S.P. Vyas

Related books